Theravance's telavancin meets Phase II endpoints

THRX said in the Phase II FAST trial, its telavancin ( TD-6424) met

Read the full 134 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE